A novel gene-pair signature for relapse-free survival prediction in colon cancer
Authors Chen P, Wang F, Zhang Z, Nie J, Liu L, Feng J, Zhou R, Wang H, Liu J, Zhao Q
Received 4 June 2018
Accepted for publication 31 July 2018
Published 3 October 2018 Volume 2018:10 Pages 4145—4153
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 4
Editor who approved publication: Dr Antonella D'Anneo
Peng-fei Chen,1–3,* Fan Wang,1,2,* Zi-xiong Zhang,4,* Jia-yan Nie,1,2 Lan Liu,1,2 Jue-rong Feng,1,2 Rui Zhou,1,2 Hong-ling Wang,1,2 Jing Liu,1,2 Qiu Zhao1,2
1Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; 2Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan 430071, China; 3Department of Gastroenterology, The Central Hospital of Enshi Autonomous Prefecture, Enshi 445000, China; 4Department of Otolaryngology, The Central Hospital of Enshi Autonomous Prefecture, Enshi 445000, China
*These authors contributed equally to this work
Background: Colon cancer (CC) patients with early relapse usually have a poor prognosis. In this study, we aimed to identify a novel signature to improve the prediction of relapse-free survival (RFS) in CC.
Methods: Four microarray datasets were merged into a training set (n=1,045), and one RNA-sequencing dataset was used as a validation set (n=384). In the training set, microarray meta-analysis screened out 596 common RFS-related genes across datasets, which were used to construct 177,310 gene pairs. Then, the LASSO penalized generalized linear model identified 16 RFS-related gene pairs, and a risk score was calculated for each sample according to the model coefficients.
Results: The risk score demonstrated a good ability in predicting RFS (area under the curve [AUC] at 5 years: 0.724; concordance index [C-index]: 0.642, 95% CI: 0.615–0.669). High-risk patients showed a poorer prognosis than low-risk patients (HR: 3.519, 95% CI: 2.870–4.314). Subgroup analysis reached consistent results when considering multiple confounders. In the validation set, the risk score had a similar performance (AUC at 5 years: 0.697; C-index: 0.696, 95% CI: 0.627–0.766; HR: 2.926, 95% CI: 1.892–4.527). When compared with a 13-gene signature, a 15-gene signature, and TNM stage, the score showed a better performance (P<0.0001; P=0.0004; P=0.0125), especially for the patients with a longer follow-up (R2=0.988, P<0.0001). When the follow-up was >5 years (n=314), the score demonstrated an excellent performance (C-index: 0.869, 95% CI: 0.816–0.922; HR: 13.55, 95% CI: 7.409–24.78).
Conclusion: Our study identified a novel gene-pair signature for prediction of RFS in CC.
Keywords: colon cancer, relapse-free survival, gene pair, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]